Price T Rowe Associates 13F: Cuts ALNY Stake by $81M
Price T Rowe Associates trimmed its holdings in Alnylam Pharmaceuticals by 15.9%, now holding 1.43 million shares.
Reviewed by automated data checks against the source filing. How we make and check alerts
Price T Rowe Associates sold 270,083 shares from its stake in Alnylam Pharmaceuticals, Inc. ($ALNY), a 15.86% decrease, according to a 13F filing with the SEC dated May 15, 2026. It reported 1,432,748 shares worth $427.10 million at the end of the quarter.
Since the filing, $ALNY is up 3.6% after 1 week, up 0.3% after 1 month and down 19.2% to date (from the $286.98 close on May 15, 2026).
Find the original: Price T Rowe Associates 13F filings on SEC EDGAR
ALNY
Alnylam Pharmaceuticals, Inc.
Key Points
- Price T Rowe Associates reduced its position in Alnylam Pharmaceuticals by 270,083 shares, a 15.9% decrease, leaving it with 1,432,748 shares valued at $427.5 million.
- Alnylam Pharmaceuticals, trading at $298.4 on Thursday, has a market cap of $38.2 billion and a P/E ratio of 72.
- Insiders at Alnylam Pharmaceuticals, including David Pyott and Benjamin Cravatt, were active with multiple transactions on June 1, 2026.
Get $ALNY trade alerts by text
We text you when insiders, Congress or big funds trade $ALNY. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Alnylam Pharmaceuticals, Inc. alert may contain errors. Disclosures
Price T Rowe Associates has reduced its stake in Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY) by 270,083 shares, a 15.9% decrease, according to its latest Form 13F filing with the SEC. This reduction leaves the firm with 1,432,748 shares, valued at approximately $427.5 million as of the reporting period ending May 15, 2026.
Price T Rowe Associates vs. the S&P 500
Hypothetical returns from Price T Rowe Associates's disclosed trades, not real profit or advice. How we model this.
What Changed in Price T Rowe Associates' Alnylam Pharmaceuticals Position
Price T Rowe Associates trimmed its holdings in Alnylam Pharmaceuticals from 1,702,831 shares to 1,432,748 shares, reducing its position by 15.9%. The value of this position is now around $427.5 million.
Other Institutional Activity in Alnylam Pharmaceuticals
FMR LLC cut its holdings in Alnylam Pharmaceuticals by 1,322,983 shares, ending with 14,579,166 shares valued at about $4.82 billion. CAPITAL WORLD INVESTORS significantly reduced its stake by 5,499,424 shares, now holding 10,802,348 shares worth $3.57 billion. In contrast, BLACKROCK, INC. slightly increased its position by 44,034 shares, holding 10,444,908 shares valued at $3.46 billion. CAPITAL RESEARCH GLOBAL INVESTORS added 2,691,473 shares, bringing its total to 9,471,181 shares, valued at $3.13 billion. VANGUARD PORTFOLIO MANAGEMENT LLC opened a new position with 6,491,280 shares worth approximately $2.15 billion.
Alnylam Pharmaceuticals, Inc. Stock Up 24.4%
Shares of Alnylam Pharmaceuticals traded near $298.4 on Thursday. The company has a market cap of $38.2 billion, a P/E ratio of 72, and a beta of 0.267. Its 52-week range is between $273.11 and $495.55, with a 50-day moving average of $300.55 and a 200-day moving average of $374.39. The company's current ratio is 3.13, and it has a quick ratio of 2.89 and a debt-to-equity ratio of 276.20.
Recent Earnings
Alnylam Pharmaceuticals reported revenue of approximately $4.29 billion, with a revenue growth of 96.4%. Its earnings per share (EPS) stand at $3.98, with a net margin of 12.6% and a return on equity (ROE) of 90.4%. The next earnings report is expected on July 30, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
2 target cuts vs 1 raises.
-
EPS & revenue
EPS beat estimates by 56.5%. Revenue beat estimates by 2.7%.
-
Profit surprise
EBITDA missed by 5 percent. Operating income beat by 55 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
1 target raise, 2 target cuts.
-
Earnings quality
Gross margin down 6.1 points. Operating margin up 20.0 points. Negative free cash flow.
Earnings Call Summary
Alnylam delivered 1.17 billion dollars in total product revenue in the first quarter, marking its first quarter exceeding 1 billion dollars. The TTR franchise generated 910 million dollars, up 153 percent year over year, with U.S. revenue growing 230 percent driven by strong AMVUTTRA adoption for heart disease. Management highlighted over 90 percent patient adherence to vutrisiran and broader international success including new launches in Europe and Japan, though Germany pricing adjustments created a temporary headwind that they expect to reverse in coming quarters.
Guidance Management reaffirmed full year guidance of 4.4 to 4.7 billion dollars in TTR revenue, expecting significantly higher quarter-over-quarter growth for the rest of 2026. They also expect the rare disease portfolio to continue contributing steady growth alongside the TTR cardiomyopathy launch expansion in international markets.
Negative report. Results or guidance disappointed and expectations are likely to move lower.
Insider Buying and Selling at Alnylam Pharmaceuticals, Inc.
Several insiders were active at Alnylam Pharmaceuticals recently. On June 1, 2026, David Pyott made multiple transactions, buying 3,830 shares and selling the same amount at an average price of $299.18 in a planned sale. Benjamin Cravatt bought 4,393 shares, while Amy Schulman and Olivier Brandicourt made smaller purchases of 838 and 1,441 shares, respectively.
Analysts Set New Price Targets
On May 19, 2026, Citigroup initiated coverage on Alnylam Pharmaceuticals with a "buy" rating and a $380 price target. RBC Capital maintained its "buy" rating with a $445 target on May 1, while Wells Fargo kept a "hold" rating with a $377 target on the same day. The consensus among 25 analysts is a "buy" rating, with an average target price of $436.32.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biotechnology company that focuses on developing therapeutics based on RNA interference. It offers treatments for various conditions, including hereditary transthyretin-mediated amyloidosis and hypercholesterolemia. The company, led by CEO Dr. Yvonne L. Greenstreet, employs around 2,500 people and collaborates with firms like Regeneron and Sanofi.
Bottom Line
Price T Rowe Associates' reduction in Alnylam Pharmaceuticals highlights ongoing institutional interest in the biotechnology firm. Investors keep a close eye on such filings to gauge institutional confidence, though they reflect past positions and not necessarily current stances. Alnylam's stock performance, insider activities, and analyst ratings provide additional context for stakeholders.
Related Filing Alerts
Source: Price T Rowe Associates's 13F filing on $ALNY (May 15, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: Price T Rowe Associates 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts